Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jul 9, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has hired Gary King to fill the new position of executive VP of international operations, a job in which he will oversee expansion into Europe and other international markets. He will be responsible for sales and marketing, regulatory approval, and reimbursement, and he will execute and develop the firm's strategies on "a country-by-country" basis. King most recently was CEO of biomarker and diagnostics company AverDx, and he also was VP of international operations at Biosite.

Qiagen has appointed Ellen Sheets to serve as chief medical officer. Sheets will develop the company's biomarker and cancer diagnostics strategies. She has been VP of clinical affairs and CMO for Hologic, and joins Qiagen from Predictive Biosciences, where she was general manager and CMO. Sheets also was an associate professor at Harvard Medical School.

Ingen Biosciences has named Karine Mignon-Godefroy to lead the company's research and development efforts. As director of R&D, Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens for detecting infectious diseases found in prosthetic replacements and to develop IVD kits for clinical use.

She formerly was director of international projects in Bio-Rad's Blood Virus division, and she was R&D manager at BMD, where she developed reagents based on Luminex technologies. She also was a group leader at Chemunex, a firm that focuses on detecting microbial contamination.

Douglas White has become CEO of OpGen, taking over from Evan Jones, who had held the position on an interim basis and will remain on OpGen's board of directors. Prior to joining the firm, White was executive vice president and general manager for the diagnostics division of BG Medicine. Before that, he was chairman of the Americas management council and senior vice president of sales and marketing for the Americas at Qiagen.

Jonathan Dorfan has been named president-elect of the Okinawa Institute of Science and Technology Graduate University. Dorfan is former director of the Department of Energy's Stanford Linear Accelerator Center, now named SLAC National Accelerator Laboratory. When OIST receives its accreditation, which is expected in late 2011,and formally becomes a university, he will become the university's first president and CEO of the OIST School Corporation.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.